A powerful new HIV prevention method is coming to Kenya—and it only requires two shots a year. Lenacapavir, a long-acting injectable, will offer six months of protection per dose and cost just Sh6,000. The injection will be available to the public starting January 2026, targeting those at high risk of infection, especially young women and adolescent girls. Health experts call it a game-changer for those who struggle with daily HIV prevention pills. Kenya is one of nine African countries selected for early rollout. As the country prepares to roll it out in 2026, Lenacapavir could become a lifesaver for many—especially those who have found daily pills a challenge. [Photo: Courtesy] How the Anti-HIV Shot Works Lenacapavir is a type of pre-exposure prophylaxis (PrEP) that protects against HIV infection before exposure. Unlike daily pills like Truvada or Descovy, Lenacapavir only needs to be injected twice a year. This makes it easier for people who often forget to take pills or face stigma when using them.
The drug works by blocking the virus from entering and replicating in the body’s immune cells. According to the World Health Organization (WHO), Lenacapavir is highly effective and offers one of the most reliable forms of HIV prevention currently available.
While the injection guards against HIV, it does not protect against other sexually transmitted infections (STIs). Health officials advise continued condom use and regular screening for full sexual health protection. Who Will Get the Anti-HIV Shot in Kenya The anti-HIV shot is a bold step forward in Kenya’s fight against HIV. With just two injections a year, it offers protection and freedom for millions.
As the country prepares to roll it out in 2026, Lenacapavir could become a lifesaver for many—especially those who have found daily pills a challenge. Keep informed, stay safe, and talk to your healthcare provider to see if this new option is right for you. Priority Groups Kenya has been ranked seventh globally in HIV burden, with over 1.4 million people living with the virus. Young women and adolescent girls face the highest risk of infection, particularly in high-incidence regions.
These groups will be the first to access Lenacapavir under donor-funded programs like the Global Fund, Tiko Africa, and UNAIDS. Supported by Global Health Partners The rollout will be supported by international health donors who plan to supply at least 2 million doses globally. Kenya joins eight other African countries—Nigeria, South Africa, Zimbabwe, Zambia, Lesotho, Mozambique, Uganda, and Eswatini—in the first phase of distribution.
WHO has urged all countries to include the shot in their HIV prevention package alongside condoms and daily pills. Kenya’s Head of Preventive and Promotive Health, Dr. Andrew Mulwa, confirmed the country’s readiness to begin distribution by January 2026. Cost and Accessibility The expected price for the injection in Kenya is Sh6,000 per dose. That amounts to Sh12,000 a year — a relatively low cost when compared to the long-term burden of treating HIV. The subsidized price will be made possible by partnerships with global health agencies and pharmaceutical manufacturers. Why Lenacapavir is a Game-Changer Better Adherence Many people at high risk of HIV struggle to take daily pills consistently. Missed doses reduce the effectiveness of oral PrEP. Lenacapavir solves this by offering protection for six months per shot, cutting down the risk of user error. Fewer Stigma-Related Challenges Some individuals avoid taking daily pills because they fear being judged or misunderstood. With fewer injections, Lenacapavir reduces these interactions, helping users maintain privacy and avoid stigma. Boosting National HIV Prevention Goals By improving convenience, Lenacapavir could help Kenya achieve its national HIV prevention targets faster. The more accessible the tools are, the more likely people will use them. Experts believe this injection could significantly reduce new infections, especially among Kenya’s vulnerable youth. What You Should Know Before Getting the Anti-HIV Shot Eligibility You’ll need to visit a health facility and get tested for HIV before receiving Lenacapavir. It is only for people who are HIV-negative and want to stay protected. It may not be suitable for everyone, so consultation with a health worker is necessary. Side Effects Most people will experience only mild side effects such as pain or swelling at the injection site. Rare cases may include allergic reactions. It’s important to report any discomfort after getting the shot. Combine with Other Safe Practices Even though Lenacapavir is effective at preventing HIV, it doesn’t protect you from other STIs like gonorrhea or chlamydia. Using condoms and getting regular health checks is still essential.